| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.aspiradiagnostics.com | |
| Market Cap | 31.70 Cr. | |
| Enterprise Value(EV) | 31.32 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -2.36 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 67.43 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 10.28 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 3.00 | Calculated using Price: 30.80 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.03 Cr. | 10,293,000 Shares |
| FaceValue | 10 | |
| About Aspira Pathlab & Diagnostics Ltd. | ||
| The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. | ||
| 1 Day |
|
+0.52% |
| 1 Week |
|
-0.65% |
| 1 Month |
|
-1.44% |
| 3 Month |
|
-14.33% |
| 6 Month |
|
-16.98% |
| 1 Year |
|
-5.95% |
| 2 Year |
|
-50.20% |
| 5 Year |
|
-7.09% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 1.1 | 0.76 | -57.04 | -178.61 | -187.57 | -94.32 | 22.8 | 42.26 | -0.69 | |
| Return on Capital Employed (%) | 3.95 | 1.78 | -25.35 | -38.38 | -34.5 | -26.3 | 21.52 | 41.63 | 2.4 | |
| Return on Assets (%) | 1.05 | 0.54 | -25.76 | -40.76 | -37.93 | -29.11 | 10.58 | 29.82 | -0.5 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 4 | 4 | 6 | 0 | 5 | 4 | 8 | 13 | 13 | 11 | |
| Non Curr. Liab. | 3 | 11 | 5 | 5 | 1 | 4 | 3 | 3 | |||
| Curr. Liab. | 0 | 3 | 6 | 2 | 4 | 5 | 2 | 2 | 2 | 2 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 4 | 6 | 15 | 13 | 15 | 14 | 12 | 18 | 17 | 16 | |
| Non Curr. Assets | 1 | 11 | 11 | 13 | 11 | 8 | 11 | 11 | 11 | ||
| Curr. Assets | 4 | 6 | 4 | 2 | 2 | 3 | 4 | 7 | 6 | 5 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 4 | 6 | 15 | 13 | 15 | 14 | 12 | 18 | 17 | 16 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 1 | 4 | 8 | 8 | 15 | 20 | 14 | 13 | |||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 0 | 0 | 1 | 5 | 8 | 9 | 15 | 20 | 15 | 13 | |
| Total Expenditure | 0 | 0 | -3 | -8 | -11 | -10 | -12 | -13 | -13 | -14 | |
| PBIDT | 0 | 0 | -2 | -4 | -3 | -2 | 4 | 6 | 2 | -1 | |
| Interest | 0 | 0 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | |
| Depreciation | 0 | -1 | -1 | -2 | -1 | -2 | -2 | -2 | |||
| Taxation | 0 | 0 | 0 | ||||||||
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | -3 | -6 | -5 | -4 | 1 | 4 | 0 | -2 | |
| Adjusted EPS | 0 | 0 | -5 | -11 | -6 | -5 | 1 | 4 | 0 | -2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -1 | -5 | -3 | -2 | 6 | 2 | 0 | ||
| Cash Fr. Inv. | 0 | 0 | 0 | -10 | -1 | -2 | 0 | 0 | -1 | 0 | |
| Cash Fr. Finan. | 3 | 3 | 9 | 7 | 3 | 1 | -2 | -1 | -1 | ||
| Net Change | 0 | 3 | 2 | -3 | 1 | -2 | 0 | 3 | 0 | -1 | |
| Cash & Cash Eqvt | 0 | 3 | 5 | 3 | 0 | -2 | -2 | 1 | 1 | 1 |
|
Wed, 17 Apr 2024
Compliance Certificate As Per Regulation 7(3) Of The SEBI(LODR)Regulations 2015 For The Financial Year Ended March 31 2024. Enclosed herewith Compliance Certificate pursuant to regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the Financial Year ended March 31 2024. |
|||||||||||||||||||||
|
Wed, 10 Apr 2024
Compliance Certificate Under Regulation 40(9 & 10) Of The SEBI (LODR) Regulations 2015 For The Year Ended March 31 2024 Pursuant to regulation 40(9 & 10) of the SEBI (LODR)Regulations 2015 we enclose herewith certificate from Practicing Company Secretary for the period from April 01 2023 to March 31 2024. |
|||||||||||||||||||||
|
Tue, 09 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Krupali Shah Designation: Company Secretary EmailId: krupali.shah@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishna Talawadekar Designation: Chief Financial Officer EmailId: balkrishna.talawadekar@aspiradiagnostics.com Date: 09/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Wed, 24 Apr 2024 |
High Delivery Percentage
|
Opening at Low
|
Opening at Low for 2 Days
|
High Decrease in 3 Months
|
High Decrease in 2 Years
|
